A 30-month multicenter, phase 2b/3, randomized, open label trial to evaluate the efficacy and safety of clofazimine administered orally in addition to background regimen compared to background regimen alone in the treatment of patients with multidrug-resistant pulmonary tuberculosis

Trial Profile

A 30-month multicenter, phase 2b/3, randomized, open label trial to evaluate the efficacy and safety of clofazimine administered orally in addition to background regimen compared to background regimen alone in the treatment of patients with multidrug-resistant pulmonary tuberculosis

Recruiting
Phase of Trial: Phase II/III

Latest Information Update: 10 Jan 2017

At a glance

  • Drugs Clofazimine (Primary)
  • Indications Pulmonary tuberculosis
  • Focus Therapeutic Use
  • Sponsors Novartis
  • Most Recent Events

    • 10 Jan 2017 This trial has been Discontinued in Latvia, according to European Clinical Trials Database.
    • 10 Jan 2017 This trial has been Discontinued in Lithuania, according to European Clinical Trials Database.
    • 10 Mar 2016 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top